SOURCE-LINKED STUDY SUMMARY
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Abstract summarizedQuality not appraised
- What was studied
- A 12-week randomized, double-blind phase 1b trial in adults with type 2 diabetes compared ascending retatrutide doses with placebo and dulaglutide. Safety and tolerability were primary outcomes; glucose, weight and drug-processing measures were secondary.
- Who / model studied
- 72 participants received treatment across retatrutide groups, placebo (15 participants) and dulaglutide (five participants).
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Adverse events affected 63% with retatrutide, 60% with dulaglutide and 54% with placebo; gastrointestinal problems were most common. In the three highest retatrutide groups, HbA1c fell 1·2–1·6 percentage points more than placebo. The highest group lost 8·96 kg more than placebo.
- Limitations & context
- No author-stated limitations were available in the abstract. Of 72 treated participants, 29 discontinued prematurely.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(22)02033-5